AI Article Synopsis
- Denosumab, a monoclonal RANKL antibody, is effectively used as a neo-adjuvant treatment for giant cell tumor (GCT) of bone to minimize the need for major surgeries, particularly in adolescents.
- A case involving a 15-year-old girl with a severe Campanacci 3 GCT in the femoral head and neck demonstrates positive outcomes after 6 months of denosumab treatment, which allowed for safe surgical intervention with less risk to the joint.
- This case marks the first documented use of denosumab for GCT in this area, prompting suggestions for future studies to investigate its potential in reducing recurrence rates and broader applications in conventional GCT cases.
Article Abstract
Introduction: Denosumab is a monoclonal RANKL antibody which has been shown to be highly effective in treating giant cell tumour (GCT) of bone. We report on its use as a neo-adjuvant agent to avoid morbid surgery for an adolescent.
Presentation Of Case: We report a case of a15-year old female with a Campanacci 3 GCT involving the femoral head and neck.
Discussion: To preserve bone stock and avoid an outright hip replacement, the patient was given denosumab pre-operatively to consolidate the tumour. After receiving 6 months of treatment, a rim of cortical bone had developed to allow an extended curettage of the tumour to be performed without fear of collapse of the articular surface.
Conclusion: This is the first reported case of the use of denosumab in GCT of the femoral head and neck. We describe our experience in the neo-adjuvant use of denosumab and offer suggestions for future use. Further studies will be needed to see if denosumab has a role in conventional GCT and whether it can lead to a lowering of local recurrence rates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245664 | PMC |
| http://dx.doi.org/10.1016/j.ijscr.2014.09.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!